An observational study in Identification of Infants at Risk for Type 1 Diabetes, sponsored by Helmholtz Zentrum München. Recruiting at 1 site in Germany. Open to participants aged 1 Day to 6 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-17.
Sponsored by Helmholtz Zentrum München · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 294 studies in Diabetes Mellitus, Type 1 with a site in Germany — 22 open to participants now, 30 under way, 6 of them phase 3. Diabetes Mellitus, Type 1 · Germany.
Among the 294 studies in Diabetes Mellitus, Type 1 with a site in Germany, this one has the largest planned enrollment of the 33 observational ones that give a count, is one of 23 that started in 2017, is one of 33 observational ones, reaches primary completion later than 14 of the 29 other live ones, and was the 192nd registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →22 of the 294 studies in Diabetes Mellitus, Type 1 with a site in Germany are open now. Recruiting first, the newest first:
Bionime Corporation · Sites in Germany
Ages 18+ · Women only
Sam Chun Dang Pharm. Co. Ltd. · Sites in Germany
Ages 18–64 · Men only
Novo Nordisk A/S · Sites in Germany
Ages 18–55
Sanofi · Sites in Germany, United States, Israel and 1 more country
Sanofi · Sites in Germany, Belgium, France and 3 more countries
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 1 Day to 6 Weeks · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
294 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 112 · Phase 2 41 · Phase 3 64 · Phase 4 11
First in 1997; this study’s year is marked. 23 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000,000 is above the median of 125 across 791 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 61 across the 260 interventional studies, 1,000 across the 33 observational. Of the 255 that completed or were terminated, 82 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
231 of 294 have an industry lead sponsor. The 10 most frequent:
Helmholtz Zentrum München is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Helmholtz Zentrum München has 3 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
13 of the studies in Diabetes Mellitus, Type 1 with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07076199Phase 3Novo Nordisk A/SA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | 2027-01-25 |
| NCT07457580SanofiReal-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) | 2026-11-30 |
| NCT07160816Novo Nordisk A/SA Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar | 2027-01-20 |
| NCT06831994Universitätsklinikum Hamburg-EppendorfDigital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity | 2027-02-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 294 studies in Diabetes Mellitus, Type 1 with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Freder1k-Study will identify infants who have a high genetic risk of type 1 diabetes.
Type 1 diabetes is a common chronic disease in childhood and is increasing in incidence. Type 1 diabetes is diagnosed by hyperglycemia often in combination with symptoms of weight loss, thirst, fatigue and frequent urination, sometimes with ketoacidosis. The clinical onset is preceded by an asymptomatic phase identified by serum multiple beta-cell autoantibodies. Neonates and infants who are at increased risk to develop multiple beta-cell autoantibodies and type 1 diabetes can now be identified using genetic markers. This provides opportunity for introducing early therapies to prevent beta-cell autoimmunity and type 1 diabetes.
The Freder1k-Study will identify infants who have a high genetic risk of type 1 diabetes.
Exclusion Criteria:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
greater than 10% risk for multiple beta-cell autoantibodies/type 1 diabetes
increased risk will be identified by risk scores derived from SNPs
Time frame: one-time testing before age 6 weeks
Started Oct 2017 (actual). Primary completion is estimated for Aug 2027, 118 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Helmholtz Zentrum München